RBM6 is a nuclear RNA-binding protein that couples mRNA recognition to control of DNA double-strand break repair and chromatin-based transcriptional regulation (PMID:34718714, PMID:39344314). It contains two RNA recognition motifs that confer direct RNA-binding activity, originally shown by specific binding to poly(G) homopolymers (PMID:10353602), and genome-wide it engages a large set of mRNAs through preferential GGCGAUG and CUCU motifs, with targets enriched for proliferation- and apoptosis-associated genes whose alternative splicing depends on RBM6 (PMID:39344314). Within the nucleus RBM6 localizes to splicing speckles/interchromatin granule clusters and to nascent transcripts, with a repetitive N-terminal region that drives oligomerization and assembly of bead-like structures at the IGC periphery (PMID:21086038). RBM6 promotes homologous recombination repair through two separable activities: an alternative splicing-coupled nonstop-decay mechanism that maintains levels of the HR regulator Fe65/APBB1 (PMID:34718714), and a splicing-independent function in which its G-patch domain mediates recruitment to break sites and interaction with Rad51 to support Rad51 foci formation, with five G-patch glycine residues required for damage-site accumulation but dispensable for splicing (PMID:36941773). Consistent with this repair role, RBM6-deficient cancer cells are sensitized to ATM inhibition, PARP inhibition, and cisplatin (PMID:34718714). RBM6 additionally forms a complex with the deacetylase SIRT7 that lowers H3K18 acetylation at the OSX promoter to suppress osteogenic differentiation (PMID:33684230). A recurrent t(3;5) translocation fuses RBM6 to CSF1R, generating a constitutively active kinase fusion that drives myeloproliferative disease (PMID:17360941).